程序性细胞死亡 1 配体 1 (PD-L1) 阻断的免疫疗法对 NK/T 细胞淋巴瘤患者有效。除PD-L1外，吲哚胺2,3-双加氧酶-1（IDO1）是最有前途的免疫治疗靶点之一。通过免疫组织化学 (IHC) 从来自三个癌症中心的 230 名新诊断的 NK/T 淋巴瘤患者的组织样本中观察到高比例的 PD-L1 和 IDO1 蛋白，并且与 NK/T 淋巴瘤患者的总生存期 (OS) 较差相关。重要的是，PD-L1 和 IDO1 的共表达与 NK/T 淋巴瘤患者的较差 OS 和较短的限制性平均生存时间有关，并且是训练队列中的一个独立预后因素，并且也在 58 例 NK/T 淋巴瘤患者中得到了验证患者（GSE90597）。此外，用 PD-L1 和 IDO1 表达以及年龄构建的列线图模型可以提供简明而精确的 OS 率和中位生存时间预测。列线图模型中的高危组与验证队列中的 CD4  T 细胞浸润呈正相关，免疫抑制因子水平也是如此。因此，PD-L1 和 IDO1 高表达与 NK/T 淋巴瘤患者的 OS 较差相关。 PD-L1 和 IDO1 可能是未来 NK/T 淋巴瘤免疫检查点阻断 (ICB) 疗法的潜在靶点。© 2024。作者，获得 Springer Nature Limited 的独家许可。

Immunotherapy with programmed cell death 1 ligand 1 (PD-L1) blockade was effective in patients with NK/T-cell lymphoma. In addition to PD-L1, indoleamine 2,3-dioxygenase-1 (IDO1) is one of the most promising immunotherapeutic targets. High proportions of PD-L1 and IDO1 proteins were observed by immunohistochemistry (IHC) from 230 newly diagnosed patients with NK/T lymphoma with tissue samples from three cancer centers and were associated with poor overall survival (OS) in patients with NK/T lymphoma. Importantly, the coexpression of PD-L1 and IDO1 was related to poor OS and short restricted mean survival time in patients with NK/T lymphoma and was an independent prognostic factor in the training cohorts, and which was also validated in 58 NK/T lymphoma patients (GSE90597). Moreover, a nomogram model constructed with PD-L1 and IDO1 expression together with age could provide concise and precise predictions of OS rates and median survival time. The high-risk group in the nomogram model had a positive correlation with CD4 + T-cell infiltration in the validation cohort, as did the immunosuppressive factor level. Therefore, high PD-L1 and IDO1 expression was associated with poor OS in patients with NK/T lymphoma. PD-L1 and IDO1 might be potential targets for future immune checkpoint blockade (ICB) therapy for NK/T lymphoma.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.